WuXi Biologics Chengdu Microbial Manufacturing Site Reaches Structural Completion, Targets 2026 GMP Production

Key Takeaways

• WuXi Biologics completes structural phase of new microbial manufacturing facility in Chengdu’s Wenjiang District
• Key manufacturing equipment has arrived on-site, advancing the facility toward operational readiness
• Company targets GMP release for commercial production by end of 2026, expanding biologics manufacturing capacity in China

---

CHENGDU, China - WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced April 24, 2026, that its microbial commercial manufacturing site in Chengdu has achieved structural completion with key equipment now arriving on-site. The milestone positions the facility to begin GMP-compliant production by the end of 2026.

Facility Development Progress

The microbial manufacturing site, which broke ground in June 2025 in Chengdu’s Wenjiang District, represents a significant expansion of WuXi Biologics’ manufacturing capabilities in China. The structural completion marks the end of the construction phase, allowing the company to focus on equipment installation and validation processes.

Strategic Manufacturing Expansion

This Chengdu facility strengthens WuXi Biologics’ position as a global CRDMO by adding specialized microbial manufacturing capacity. Microbial production systems are crucial for producing recombinant proteins, vaccines, and other biologics using bacterial or yeast expression systems, offering cost-effective alternatives to mammalian cell culture for certain therapeutic proteins.

Market Impact and Timeline

The facility’s planned GMP release by end-2026 will enhance WuXi Biologics’ ability to serve both domestic Chinese and international clients requiring microbial-based biologics manufacturing. This expansion comes as demand for contract manufacturing services continues growing globally, driven by increased biologics development and companies seeking to outsource manufacturing to specialized providers.

The Chengdu location provides strategic advantages including access to skilled workforce, favorable regulatory environment, and proximity to key Asian markets. WuXi Biologics’ investment in microbial manufacturing capabilities aligns with industry trends toward diversified production platforms and increased manufacturing flexibility.

Next Steps

With structural completion achieved, WuXi Biologics will focus on equipment qualification, process validation, and regulatory inspections necessary for GMP certification. The company expects to begin commercial production operations once regulatory approvals are secured by year-end 2026.

---

Frequently Asked Questions

What is microbial manufacturing in biologics production?

Microbial manufacturing uses bacteria or yeast to produce therapeutic proteins, vaccines, and other biologics. It’s often more cost-effective than mammalian cell culture for certain products and offers faster production timelines.

When will the WuXi Biologics Chengdu facility begin production?

WuXi Biologics targets GMP release and commercial production by the end of 2026, following equipment installation, validation, and regulatory approval processes.

How does this expansion benefit WuXi Biologics’ clients?

The new facility increases manufacturing capacity and provides clients with additional microbial production options, potentially reducing costs and timelines for suitable biologics products while offering geographic diversification.